Recent advances in minimally invasive surgery for gynecologic indications.

In an effort to achieve the benefits of minimally invasive techniques, many clinicians have implemented LESS, even for oncologic surgeries. The first report of LESS for gynecologic oncology procedures was published by Fader and Escobar in 2009 [ 26 ], in which the surgical indications included various gynecologic cancers and precancerous conditions. Thereafter, several studies have demonstrated the feasibility and safety of LESS in gynecologic oncology. In a retrospective multicentric study, Fagotti et al. evaluated the effect of LESS in 100 cases of early-stage endometrial cancer [ 27 ]. This was a large-scale study of endometrial cancer treated using LESS. Pelvic and paraaortic lymphadenectomy was performed in 48 and 27 patients, respectively, and a median of 16 pelvic nodes and 7 paraaortic lymph nodes were retrieved. Eight cases of intra- or postoperative complications were found, and two conversions to MLS or open surgery were observed. Altogether, the authors concluded that LESS is feasible for treatment of early-stage endometrial cancer. Similarly, the first case of LESS radical hysterectomy for cervical cancer was reported by Garrett and Boruta in 2012 [ 28 ], and the same study group reported the first retrospective series of patients with stage I cervical cancer who were treated using LESS radical hysterectomy and pelvic lymphadenectomy [ 29 ]. The surgical outcomes were promising, as follows: 260 minutes of median operative time, 60mL of median blood loss, and 9% of conversion rate to MLS or open surgery. Finally, the authors proposed larger studies to determine whether LESS can be used in routine gynecologic oncology practice. Meanwhile, a wide peritoneal spread and frequent recurrence of ovarian cancer have limited the use of LESS. Unlike endometrial or cervical cancer, the feasibility and oncologic safety of even MLS for early-stage ovarian cancer is still under debate. It might be plausible that LESS is used merely for initial diagnosis and intra-abdominal exploration, but not for upfront surgical staging, in ovarian cancer. To date, no series of ovarian cancer treated with LESS has been reported.

Over the last two decades, minimally invasive surgery has been widely adopted, and it has become the standard procedure in gynecologic diseases. Considerable evidence indicates that owing to the non-requirement of a large abdominal incision, laparoscopic surgery offers substantial advantages over open surgery, including less postoperative pain, shorter hospital stays, faster postoperative recovery, improved cosmetic outcomes, fewer wound-related complications, and lower costs [ 1 , 2 ]. An increasing interest in even less invasive surgery has led to the advent of laparoendoscopic single-site surgery (LESS), which is also called single-port surgery or single-incision laparoscopy. During this procedure, all instruments are inserted through a single skin incision, which is almost invariably made at the umbilicus. Historically, gynecology has played a leading role in the development of LESS. The first reported case of LESS was a tubal sterilization performed by Wheeless in 1969 [ 3 ]. Approximately 20 years later, Pelosi and Pelosi [ 4 ] reported the first case of hysterectomy through LESS. Currently, LESS is used for various surgeries for gynecologic, urologic, and gastrointestinal indications. A single small incision of entry could pose technical problems to the surgeon. However, a growing body of knowledge indicates that the feasibility and safety of LESS are currently evident for more complex procedures than they were in the past, although the clinical advantages of LESS over conventional multiport laparoscopic surgery (MLS) are still under investigation. This study aimed to provide a systematic review of the recent updates on the clinical outcomes of minimally invasive procedures in gynecologic diseases. We particularly focused on the procedure of not only LESS but also natural orifice transluminal endoscopic surgery (NOTES), which is an emerging technique in minimally invasive surgery.

NOTES is a scarless single-entry surgery, which is an emerging concept in minimally invasive techniques. Although it can be performed via various access routes such as the stomach, esophagus, vagina, bladder, and rectum, the vagina has been focused on almost exclusively, as it might be the safest and most feasible route for clinical application [ 33 ]. Reported advantages of NOTES include the absence of a visible abdominal scar, less operative pain, shorter hospital stay, improved operative visibility, and possibly, no requirement of adhesiolysis to expose the pelvic organs [ 33 ]. In 2013, Yang et al. reported seven cases of transvaginal NOTES for salpingo-oophorectomy [ 34 ]. The median tumor size was 6 cm; the estimated blood loss was minimal, and the mean operative time was 45 minutes. No postoperative complication or conversion to standard laparoscopic surgery was reported, suggesting that transvaginal NOTES is feasible and safe for the treatment of adnexal masses. More recently, a meta-analysis evaluated the advantages and disadvantages of NOTES hysterectomy in patients with benign gynecological disease [ 35 ]. The study did not find RCTs but included two retrospective cohort studies comparing NOTES hysterectomy with conventional LAVH(either LESS -or MLS-LAVH). It was observed that compared to conventional LAVH, the NOTES group was associated with shorter operative time and hospital stay but higher cost. There were no differences between the groups in terms of intra- or postoperative complications and postoperative pain. No case of conversion to conventional laparoscopy or open surgery was demonstrated. The study concluded that NOTES should be considered as an option for gynecological approaches. Although the use of NOTES in gynecologic surgery is rapidly increasing, technical difficulties that must be overcome still exist. As the limitation of NOTES is mainly related to collision between instruments, a study recommended using a flexible scope or a rigid scope with at least a 30-degree lens [ 33 ].

LESS and NOTES are the emerging techniques in the evolution of minimally invasive surgery. Their technical limitations continue to lessen with the recent technological innovations, such as the robotic surgical system, various types of multi-channel ports, and articulating instruments. The feasibility and safety of LESS for benign gynecologic diseases have been demonstrated. However, the evidence is not strong enough to recommend the use of LESS over MLS, as the definitive superiority of LESS has not been established. Based on the result of the most recently published meta-analysis, the majority of surgical outcomes are equivalent between LESS and MLS, except for the longer operative time required for LESS than for MLS for both adnexal surgery and hysterectomy. Although several studies have been reporting on robotic LESS, NOTES, and LESS for gynecologic malignancy, definite conclusions with regard to their safety and efficacy have not been drawn owing to the lack of information. The clinically relevant benefits and risks of LESS could vary according to the individual institution or surgeon. The available literature highlights the statistical limitation of the analysis as well as the major differences in the surgical techniques and the equipment used among the studies published. Extensive experience with minimally invasive surgery, especially MLS, has already been accumulated. However, future well-designed large-scale research is necessary to determine the effectiveness of LESS as well as R-LESS and NOTES for gynecologic malignancies. An indication and absolute contraindication should also be ascertained before the widespread use of these procedures.

Although the surgical indication for MLS has slowly extended to more advanced gynecologic pathologies, robotic minimally invasive surgery has been rapidly utilized in various gynecologic diseases. Less than 10 years ago, the first report of R-LESS in gynecology introduced risk-reducing bilateral salpingo-oophorectomy and total hysterectomy performed in a woman with breast cancer [ 30 ]. In 2014, the Food and Drug Administration approved R-LESS instruments for use in benign hysterectomy and salpingo-oophorectomy. Recently, R-LESS is becoming more standardized and is increasingly used by surgeons despite a technical limitation attributed to the absence of EndoWrist technology, unlike the robotic MLS platform [ 31 ]. In 2018, a systemic review described the surgical outcomes of 810 cases of R-LESS hysterectomy performed for non-neoplastic disease [ 31 ]. Although the operative time of and blood loss associated with the procedure were tolerable, definite conclusions regarding postoperative pain and cosmetic results remained unknown owing to the lack of sufficient information. Complications and conversion to open surgery were reported in 4.9% and 2.8% of the patients, respectively. In terms of learning curve, the study found that a proficiency in vaginal cuff suture can be achieved after 14 cases, and that both large uterus and previous abdominal surgery are limitations of R-LESS hysterectomy. A previous study by Lopez et al. retrospectively compared R-LESS and LESS hysterectomy for benign indications in 100 patients [ 32 ]. The rate of conversion to multiport procedures was 16% in the R-LESS group and 10% in the LESS group, without a statistically significant difference. There were no conversions to open surgery. Blood loss was equivalent between the two groups; however, the operative time was 24.9 minutes longer in the R-LESS group. Several studies have shown the feasibility and safety of R-LESS procedures. However, most of these studies are case series or retrospective cohort studies. Further evidence in this regard is warranted.